Top

Published in:

01-06-2019 | Esophageal Cancer | Original Article

Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study

Authors: Makoto Sakai, Makoto Sohda, Hideyuki Saito, Kengo Kuriyama, Tomonori Yoshida, Yuji Kumakura, Keigo Hara, Takehiko Yokobori, Tatsuya Miyazaki, Kazutoshi Murata, Shin-ei Noda, Takashi Nakano, Hiroyuki Kuwano, Ken Shirabe

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2019

Abstract

Background

To evaluate the efficacy of docetaxel, cisplatin, and 5-fluorouracil as combination chemoradiotherapy (DCF-RT) for cervical esophageal cancer (CEC), we performed a retrospective analysis of CEC patients treated by DCF-RT at a single institution.

Methods

We conducted a single-center retrospective study. Twenty-one patients with CEC who underwent DCF-RT between 1999 and 2017 at our institute were included in this study. Chemotherapy consisted of intravenous docetaxel at 50 mg/m² on day 1, intravenous CDDP at 60 mg/m² on day 1, and intravenous 5-FU at 600 mg/m² on days 1–4, repeated every 4 weeks for two cycles. Among the 21 patients, six were irradiated using three-dimensional conformal RT (3D- conformal RT) and 15 were treated using intensity-modulated RT (IMRT) consisting of 60 Gy in 30 fractions.

Results

The median follow-up period was 49.6 months (range 4.6–97.6). The overall complete response (CR) and local CR rates were 61.9% and 81.0% for all patients, and 76.9% and 84.6% for patients without hypopharyngeal and/or thoracic esophageal invasion, respectively. The 3-year overall survival (OS), progression-free survival (PFS), and local failure-free survival (LFFS) rates were 79.6, 52.4, and 74.7%, respectively. Grade 3–4 leucopenia developed in 12 patients (70.6%), neutropenia developed in 13 patients (81.2%), and mucositis developed in 2 patients (9.5%). There were no treatment-related deaths.

Conclusions

The 3-year OS and LFFS of patients who underwent DCF-RT were higher than those in the previous studies. Although the high rate of myelosuppression requires careful management, DCF-RT is a safe and effective modality for CEC.

Sombeck MD, Parsons JT et al (1994) Management of cervical esophageal carcinoma. Semin Radiat Oncol 4:179–191. https://doi.org/10.1053/SRAO00400179 CrossRefPubMed

Kuwano H, Nishimura Y, Oyama T et al (2015) Guidelines for diagnosis and treatment of carcinoma of the Esophagus April 2012 edited by the Japan esophageal society. Esophagus. https://doi.org/10.1007/s10388-014-0465-1 CrossRefPubMed

Ajani JA, D’Amico TA, Almhanna K et al (2015) Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw 13:194–227CrossRef

Yamada K, Murakami M, Okamoto Y et al (2006) Treatment results of radiotherapy for carcinoma of the cervical esophagus. Acta Oncol (Madr) 45:1120–1125. https://doi.org/10.1080/02841860600609768 CrossRef

Zhang P, Xi M, Zhao L et al (2015) Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol 116:257–261. https://doi.org/10.1016/j.radonc.2015.07.011 CrossRefPubMed

Zenda S, Kojima T, Kato K et al (2016) Multicenter phase 2 study of cisplatin and 5-fluorouracil with concurrent radiation therapy as an organ preservation approach in patients with squamous cell carcinoma of the cervical esophagus. Int J Radiat Oncol Biol Phys 96:976–984. https://doi.org/10.1016/j.ijrobp.2016.08.045 CrossRefPubMed

Ito M, Kodaira T, Tachibana H et al (2017) Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: comparison of failure pattern and toxicities between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy. Head Neck 39:2406–2415. https://doi.org/10.1002/hed.24909 CrossRefPubMed

Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT 0123 (radiation therapy oncology Group 94-05) phase III trial of combined-Modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167–1174. https://doi.org/10.1200/JCO.2002.20.5.1167 CrossRefPubMed

Kato K, Eguchi Nakajima T, Ito Y et al (2013) Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for stage II-III esophageal carcinoma. Jpn J Clin Oncol 43:608–615. https://doi.org/10.1093/jjco/hyt048 CrossRefPubMed

10.

Ishida K, Ando N, Yamamoto S et al (2004) Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan esophageal oncology group (JEOG)/Japan clinical oncology group trial (JCOG9516). Jpn J Clin Oncol 34:615–619. https://doi.org/10.1093/jjco/hyh107 CrossRefPubMed

11.

Miyazaki T, Sohda M, Tanaka N et al (2015) Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer. Cancer Chemother Pharmacol 75:449–455CrossRef

12.

Japan Esophageal Society JE (2017) Japanese classification of esophageal cancer, 11th edition: part II and III. Esophagus 14:37–65. https://doi.org/10.1007/s10388-016-0556-2 CrossRef

13.

Sobin L, Gospodarowicz M WC (2009) TNM Classification of Malignant Tumours, 7th Edition. In: Wiley

14.

Cao C, Luo J, Gao L et al (2015) Definitive radiotherapy for cervical esophageal cancer. Head Neck 37:151–155. https://doi.org/10.1002/hed.23572 CrossRefPubMed

15.

Huang SH, Lockwood G, Brierley J et al (2008) Effect of concurrent high-dose cisplatin chemotherapy and conformal radiotherapy on cervical esophageal cancer survival. Int J Radiat Oncol 71:735–740. https://doi.org/10.1016/j.ijrobp.2007.10.022 CrossRef

16.

Zhao L, Zhou Y, Mu Y et al (2017) Patterns of failure and clinical outcomes of definitive radiotherapy for cervical esophageal cancer. Oncotarget. https://doi.org/10.18632/oncotarget.15665 CrossRefPubMedPubMedCentral

17.

Katori H, Tsukuda M (2005) Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck. Clin Oncol 17:148–152. https://doi.org/10.1016/j.clon.2004.09.013 CrossRef

18.

Tamaki Y, Hieda Y, Nakajima M et al (2018) Concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil improves survival of patients with advanced esophageal cancer compared with conventional concurrent chemoradiotherapy with cisplatin and 5-fluorouracil. J Cancer 9:2765–2772. https://doi.org/10.7150/jca.23456 CrossRefPubMedPubMedCentral

19.

Bedford JL, Viviers L, Guzel Z et al (2000) A quantitative treatment planning study evaluating the potential of dose escalation in conformal radiotherapy of the oesophagus. Radiother Oncol 57:183–193CrossRef

20.

Higuchi K, Komori S, Tanabe S et al (2014) Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys 89:872–879. https://doi.org/10.1016/j.ijrobp.2014.03.030 CrossRefPubMed

Title: Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study
Authors: Makoto Sakai
Makoto Sohda
Hideyuki Saito
Kengo Kuriyama
Tomonori Yoshida
Yuji Kumakura
Keigo Hara
Takehiko Yokobori
Tatsuya Miyazaki
Kazutoshi Murata
Shin-ei Noda
Takashi Nakano
Hiroyuki Kuwano
Ken Shirabe
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Keywords: Esophageal Cancer
Esophageal Cancer
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03835-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2019

First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma

De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer

Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients

d,l-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro

Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer

Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer